$UPC

Universe Pharmaceuticals INC

Universe Pharmaceuticals is a pharmaceutical company based in Jiangxi, China, that manufactures, markets, sells and distributes traditional Chinese medicine derivative (TCMD) products, primarily targeting older adults. It produces 13 varieties of its own products, including treatments for chronic conditions and cold and flu medicines. Its brands include Bai Nian Dan and Hu Zhuo Ren, and Guben Yanling Pill is its signature product. Through its subsidiary Universe Trade, it also distributes and sells third-party biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces and dietary supplements. Universe makes money by selling its own manufactured products and distributing third-party pharmaceutical products to distributors, hospitals, clinics and drugstore chains. Its products are sold in 261 cities across 30 provinces in China. The Cayman Islands holding company has no operations of its own; operating activities are conducted in China through its subsidiaries. Its principal executive offices are in Ji’an, Jiangxi Province, China.

No enriched coverage for $UPC in the last 7 days.

No SEC Form 4 filings for $UPC in the last 30 days.

See all $UPC insider activity →
Med

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

Top Biotech Gainers: UPC Cuts Loss, CPIX Gains Ahead Of Q2 Results, AUTL Builds Commercial Momentum

Biotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI

UPC sentiment & insider activity

Recent UPC coverage spans market movers, financial news and mergers & acquisitions.

What's driving UPC

  • Significant ownership disclosure may trigger short covering and volatility.

    rttnews.com · Sep 2, 2026

  • New sizable block ownership could influence voting outcomes and potential takeover interest.

    stocktitan.net · Sep 1, 2026

  • Loss narrowed materially, which can support sentiment and near-term positioning ahead of future updates.

    rttnews.com · Aug 4, 2026

  • Acquisition-backed IP expansion is a fresh M&A catalyst that can re-rate UPC’s growth/defensibility narrative ahead of closing.

    rttnews.com · Jun 30, 2026

  • M&A stock consideration and a patent-portfolio expansion are likely to drive near-term sentiment and volatility, with execution risk into Q3 2026.

    rttnews.com · Jun 27, 2026

AlphAI scores every news story that mentions UPC with an AI model for sentiment and relevance, and aggregates insider trades from Universe Pharmaceuticals INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $UPC

Score

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

Top Biotech Gainers: UPC Cuts Loss, CPIX Gains Ahead Of Q2 Results, AUTL Builds Commercial Momentum

Biotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI

Top Biotech Gainers: UPC Expands Patent Portfolio, All Eyes On SLS, What's Behind The QDEL Rumor?

Biotech gainers highlighted: Universe Pharma (UPC) surged 311% after agreeing to buy Best Praise International for $10.75M in shares to expand its China patent portfolio; Decoy Therapeutics (DCOY) rose 74% on a PIPE up to $21M; QuidelOrtho (QDEL) gained 32% on reports it may sell its point-of-care unit for about $1.5B; SELLAS (SLS) jumped 25% ahead of AML trial readouts.

$UPCMedAI 8/10

Universe Pharmaceuticals To Acquire Best Praise International For Patent Expansion; Shares Surge

Universe Pharmaceuticals (UPC) signed a share purchase agreement to acquire Best Praise International Limited, which holds five China pharmaceutical patents, for about US$10.75 million. The payment will be made via 4,376,552 Class A ordinary shares. UPC says the patents broaden its pipeline in areas including cognitive, cardiovascular, and drug delivery. The deal is board-approved and expected to close in Q3 2026.

Gang Lai Discloses Stake at Universe Pharmaceuticals with 13.58% Holding

Gang Lai, CEO and Chairman of Universe Pharmaceuticals INC, has disclosed a 13.58% stake in the company's Class A stock. This significant holding, acquired through an equity grant and control of a BVI holding company, enhances his ability to influence company strategy, governance, and potential corporate actions. While he reports no immediate plans for corporate changes, his position grants him meaningful influence over the company's future direction.

Universe Pharmaceuticals Faces Uncertain Market as Growth Struggles Persist

Universe Pharmaceuticals (UPC) is experiencing an uncertain market despite a recent stock increase of 26.95%. The company shows strong top-line growth with $23 million in revenue and a low price-to-sales ratio, suggesting undervaluation. However, high leverage, negative return on invested capital, and significant debt levels raise concerns about financial resilience and profitability, necessitating strategic interventions to improve retained earnings and operational efficiency.

Related tickers